Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities

Journal of Infectious Diseases

Volumn 201, Issue 3, 2010, Pages 378-385

  Hagan, Holly ^a,g   Pouget, Enrique R ^b   Williams, Ian T ^c   Garfein, Richard L ^c,d   Strathdee, Steffanie A ^d   Hudson, Sharon M ^e   Latka, Mary H ^g   Ouellet, Lawrence J ^f  

^a NEW YORK UNIVERSITY   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f AURUM INSTITUTE   (South Africa)

^g NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; HAZARD RATIO; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; UNITED STATES; CLINICAL TRIAL; IMMUNOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; SUBSTANCE ABUSE; VIROLOGY;

ADOLESCENT; ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; YOUNG ADULT;

EID: 75649134628     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/649783     Document Type: Article

References (34)

1. Hagan H, Thiede H, Des Jarilais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS 2005; 19(Suppl 3): S199-S207. (Pubitemid 41682188)
2. Hagan H. Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-46. (Pubitemid 32049265)
3. Smyth BP, Barry J, Keenan E. Irish injecting drug users and hepatitis C: the importance of the social context of injecting. Int J Epidemiol 2005; 34: 166-172. (Pubitemid 40347389)
4. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995; 332: 444-451.
5. Garten RJ, Lai S, Zhang J, et al. Rapid transmission of hepatitis C virus among young injection drug users in Southern China. Int J Epidemiol 2004; 33: 182-188. (Pubitemid 38500175)
6. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 2000; 16: 1043-1049. (Pubitemid 34815008)
7. Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in southwestern Sydney, Australia. J Gastroenterol Hepatol 2004; 19: 1114-1120. (Pubitemid 39371252)
8. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust NZJ Public Health 2007; 31: 30-35.
9. Roy E, Alary M, Morissette C, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. SurvUDI Working Group. Int J STD AIDS 2007; 18: 23-27. (Pubitemid 46310246)
10. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002; 186: 1558-1564. (Pubitemid 35379631)
11. Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav 2005; 9: 27-39. (Pubitemid 40562182)
12. Falster K, Kaldor JM, Maher L. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated crosssectional survey of needle and syringe program attendees in Australia, 1995-2004. Collaboration of Australian Needle and Syringe Programs. J Urban Health 2009; 86(1): 106-118.
13. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Metaregression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099-1109.
14. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14: 605-611. (Pubitemid 30209702)
15. Sattar SA, Tetro J, Springthorpe VS, Giulivi A. Preventing the spread of hepatitis B and C viruses: where are germicides relevant? Am J Infect Control 2001; 29: 187-197.
16. Krawczynski K, Alter MJ, Robertson BH, Lu L, Spelbring JE, McCaustland 6KA. Environmental stability of hepatitis C virus (HCV): viability of dried/stored HCV in chimpanzee infectivity studies. In: Proceedings of the 54th Annual Meeting of the American Society for the Study of Liver Disease (Alexandria, Va) Washington, DC: American Society for the Study of Liver Diseases, 2003.
17. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-653. (Pubitemid 34246097)
18. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101: 1499-1508. (Pubitemid 44337774)
19. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-742. (Pubitemid 34977186)
20. Lucidarme D, Bruandet A. Ilef D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 2004; 132: 699-708.
21. Brewer DD, Hagan H, Sullivan DG, et al. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors. J Infect Dis 2006; 194: 764-772. (Pubitemid 44344123)
22. Koester S, Heimer R, Barón AE, Glanz J, Teng W. Re: "Risk of hepatitis C virus among young adult injection drug users who share injection equipment." Am J Epidemiol 2003; 157: 376.
23. Simoes AA, Bastos FI, Moreira RI, Lynch KG, Metzger DS. A randomized trial of audio computer and in-person interview to assess HIV risk among drug and alcohol users in Rio De Janeiro, Brazil. J Subst Abuse Treat 2006; 30: 237-243.
24. Ghanem KG, Hutton HE, Zenilman JM, Zimba R, Erbelding EJ. Audio computer assisted self interview and face to face interview modes in assessing response bias among STD clinic patients. Sex Transm Infect 2005; 81: 421-425. (Pubitemid 41494359)
25. Garfein RS, Swartzendruber A, Ouellet LJ, et al. Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT). DUIT Study Team. Drug Alcohol Depend 2007; 91(Suppl 1): S4-S17. (Pubitemid 47470024)
26. SAS/STAT user's guide. Version 8. Cary, NC: SAS Institute, 1999.
27. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998; 88: 15-19.
28. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-936.
29. Bailey SL, Ouellet LJ, Mackesy-Amiti ME, et al. Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U. S. cities. Drug Alcohol Depend 2007; 91(Suppl 1): S18-S29.
30. Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction 2008; 103: 1593-1603.
31. Thiede H, Hagan H, Campbell JV, et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U. S. cities. Drug Alcohol Depend 2007; 91(Suppl 1): S39-S47. (Pubitemid 47470022)
32. Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. DUIT Study Team. AIDS 2007; 21: 1923-1932. (Pubitemid 47329769)
33. Friedman SR, Mateu-Gelabert P, Sandoval M, Hagan H, Des Jarlais DC. Positive deviance control-case life history: a method to develop grounded hypotheses about successful long-term avoidance of infection. BMC Public Health 2008; 8: 94. (Pubitemid 351581168)
34. Rhodes T, Kimber J, Small W, et al. Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction 2006; 101: 1384-1393.